Target intelligence / Profile preview

S-ribosylhomocysteine lyase (LuxS)

Target
LuxS
Molecular classification
Enzyme, Carbon-sulfur lyase, Metalloenzyme
01

Overview

S-ribosylhomocysteine lyase (LuxS) is an iron-dependent metalloenzyme (EC 4.4.1.21) found in many bacteria that cleaves S-ribosylhomocysteine to produce L-homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD), the precursor of the universal bacterial signaling molecule autoinducer-2 (AI-2)[1][2][4][7]. LuxS plays a key role in bacterial quorum sensing, a system of cell communication based on cell density that regulates biofilm formation, virulence, antibiotic resistance, and other group behaviors. It is highly conserved and encoded by the luxS gene in most bacteria[1][2][7]. LuxS belongs to the carbon-sulfur lyase class and requires a metal cofactor, commonly Fe2+, for its catalytic activity[1][3][5][10]. The enzyme is of significant interest as a potential antibacterial drug target due to its central role in regulating multicellular behaviors in pathogenic bacteria[3][5][7].

Other names
S-ribosylhomocysteinaseLuxSS-(5-deoxy-D-ribos-5-yl)-L-homocysteine L-homocysteine-lyase [(4S)-4,5-dihydroxypentan-2,3-dione-forming]
02

Mechanism of action

Inhibition of quorum sensing, Disruption of AI-2 signaling pathway, Interference with bacterial communication and virulence

03

Biological functions

Quorum sensingMethionine metabolismAutoinducer-2 (AI-2) synthesisDetoxification of S-adenosylhomocysteineCell-cell communication in bacteria
04

Disease associations

InfectionBiofilm formation-related diseasesBacterial virulence
05

Safety considerations

Targeting may affect beneficial microbiotapotential bacterial resistanceenzyme is absent in humans, reducing risk of human toxicity but off-target host-microbe effects possible
06

Interacting drugs

Potential anti-bacterial agents (not clinically approved, but the enzyme is suggested as a target for antibacterial drug development)
07

Biomarkers

AI-2 levels (as a marker of LuxS activity and quorum sensing)Biofilm formation capabilityBacterial virulence (in some pathogens)

Beyond the preview

Go deeper on S-ribosylhomocysteine lyase (LuxS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-ribosylhomocysteine lyase (LuxS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call